Department of Internal Medicine, Frankel Cardiovascular Center (Z.C., G.Z., Y.Z., H.L., W.X., W.L., J.S., H.W., T.Z., O.R., Y.G., Y.F., L.C., M.T.G.-B., Y.E.C., J.Z.), University of Michigan Medical Center, Ann Arbor.
Department of Metabolism and Endocrinology (Z.C.), The Second Xiangya Hospital, Central South University, Changsha, Hunan, P.R. China.
Arterioscler Thromb Vasc Biol. 2020 Oct;40(10):2494-2507. doi: 10.1161/ATVBAHA.120.314955. Epub 2020 Aug 13.
Currently, there are no approved drugs for abdominal aortic aneurysm (AAA) treatment, likely due to limited understanding of the primary molecular mechanisms underlying AAA development and progression. BAF60a-a unique subunit of the SWI/SNF (switch/sucrose nonfermentable) chromatin remodeling complex-is a novel regulator of metabolic homeostasis, yet little is known about its function in the vasculature and pathogenesis of AAA. In this study, we sought to investigate the role and underlying mechanisms of vascular smooth muscle cell (VSMC)-specific BAF60a in AAA formation. Approach and Results: BAF60a is upregulated in human and experimental murine AAA lesions. In vivo studies revealed that VSMC-specific knockout of BAF60a protected mice from both Ang II (angiotensin II)-induced and elastase-induced AAA formation with significant suppression of vascular inflammation, monocyte infiltration, and elastin fragmentation. Through RNA sequencing and pathway analysis, we found that the expression of inflammatory response genes in cultured human aortic smooth muscle cells was significantly downregulated by small interfering RNA-mediated BAF60a knockdown while upregulated upon adenovirus-mediated BAF60a overexpression. BAF60a regulates VSMC inflammation by recruiting BRG1 (Brahma-related gene-1)-a catalytic subunit of the SWI/SNF complex-to the promoter region of NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) target genes. Furthermore, loss of BAF60a in VSMCs prevented the upregulation of the proteolytic enzyme cysteine protease CTSS (cathepsin S), thus ameliorating ECM (extracellular matrix) degradation within the vascular wall in AAA.
Our study demonstrated that BAF60a is required to recruit the SWI/SNF complex to facilitate the epigenetic regulation of VSMC inflammation, which may serve as a potential therapeutic target in preventing and treating AAA.
目前尚无治疗腹主动脉瘤(AAA)的批准药物,这可能是由于对 AAA 发展和进展的主要分子机制了解有限。BAF60a-一种独特的 SWI/SNF(转换/蔗糖非发酵)染色质重塑复合物亚基-是代谢稳态的新型调节剂,但它在血管中的功能及其在 AAA 发病机制中的作用知之甚少。在这项研究中,我们试图研究血管平滑肌细胞(VSMC)特异性 BAF60a 在 AAA 形成中的作用和潜在机制。
BAF60a 在人及实验性鼠 AAA 病变中上调。体内研究表明,血管平滑肌细胞特异性 BAF60a 敲除可保护小鼠免受 Ang II(血管紧张素 II)诱导和弹性蛋白酶诱导的 AAA 形成,同时显著抑制血管炎症、单核细胞浸润和弹性蛋白片段化。通过 RNA 测序和通路分析,我们发现,在培养的人主动脉平滑肌细胞中,小干扰 RNA 介导的 BAF60a 敲低显著下调炎症反应基因的表达,而腺病毒介导的 BAF60a 过表达则上调。BAF60a 通过将 BRG1(SWI/SNF 复合物的催化亚基)募集到 NF-κB(核因子 kappa-轻链增强子的激活 B 细胞)靶基因的启动子区域,调节 VSMC 炎症。此外,VSMCs 中 BAF60a 的缺失阻止了蛋白水解酶半胱氨酸蛋白酶 CTSS(组织蛋白酶 S)的上调,从而改善 AAA 血管壁内 ECM(细胞外基质)降解。
我们的研究表明,BAF60a 是募集 SWI/SNF 复合物以促进 VSMC 炎症的表观遗传调节所必需的,这可能成为预防和治疗 AAA 的潜在治疗靶点。